OncoMatch/Clinical Trials/NCT05566054
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
Is NCT05566054 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Chidamide and Azacitidine for acute monocytic leukemia.
Treatment: Chidamide · Azacitidine · Venetoclax — This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: radiotherapy
Did not receive radiotherapy, chemotherapy, targeted therapy or hematopoietic stem cell transplantation within 4 weeks before enrollment
Cannot have received: chemotherapy
Did not receive radiotherapy, chemotherapy, targeted therapy or hematopoietic stem cell transplantation within 4 weeks before enrollment
Cannot have received: targeted therapy
Did not receive radiotherapy, chemotherapy, targeted therapy or hematopoietic stem cell transplantation within 4 weeks before enrollment
Cannot have received: hematopoietic stem cell transplantation
Did not receive radiotherapy, chemotherapy, targeted therapy or hematopoietic stem cell transplantation within 4 weeks before enrollment
Lab requirements
Kidney function
Creatinine clearance >= 30 mL/min to < 45 mL/min (inclusion); Exclusion: serum creatinine > 1.5 × ULN
Liver function
Moderate hepatic impairment with total bilirubin > 1.5 to <= 3.0 × ULN (inclusion); Exclusion: total bilirubin > 1.5 × ULN, ALT/AST > 2.5 × ULN or > 1.5 × ULN with liver involvement
Cardiac function
Cardiac history of congestive heart failure requiring treatment or ejection fraction <= 50% or chronic stable angina (inclusion); Exclusion: QTc prolongation (male > 450 ms; female > 470 ms), ventricular tachycardia, atrial fibrillation, II-degree heart block, MI within 1 year, congestive heart failure, symptomatic coronary heart disease requiring treatment
Cardiac history of congestive heart failure requiring treatment or ejection fraction <= 50% or chronic stable angina. Moderate hepatic impairment with total bilirubin > 1.5 to <= 3.0 × ULN. Creatinine clearance >= 30 mL/min to < 45 mL/min. Liver function abnormalities (total bilirubin > 1.5 × ULN, ALT/AST > 2.5 × ULN or with liver involvement ALT/AST > 1.5 × ULN), or renal anomalies (serum creatinine > 1.5 × ULN).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify